Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms

被引:4
|
作者
Braunstein, Evan M. [1 ]
Chen, Hang [1 ]
Juarez, Felicia [1 ]
Yang, Fanghan [1 ]
Tao, Lindsay [1 ]
Makhlin, Igor [2 ]
Williams, Donna M. [1 ]
Chaturvedi, Shruti [1 ]
Pallavajjala, Aparna [3 ]
Karantanos, Theodoros [4 ]
Martin, Renan [5 ]
Wohler, Elizabeth [5 ]
Sobreira, Nara [5 ]
Gocke, Christopher D. [3 ,4 ]
Moliterno, Alison R. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Haematol, Baltimore, MD 21205 USA
[2] Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Med Oncol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, McKusick Nathans Dept Genet Med, Baltimore, MD 21205 USA
关键词
familial cancer; myeloproliferative neoplasms; germline predisposition; BREAST-CANCER; INHERITED SUSCEPTIBILITY; JAK2; HAPLOTYPE; MUTATIONS; COMMON; PREDISPOSITION; POLYMORPHISM; GENE;
D O I
10.3390/cancers13133246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Familial clustering of myeloproliferative neoplasms (MPN) is well known, with a 5- to 7-fold increased risk of MPN among first-degree relatives of MPN patients. However, the genetic susceptibility of this disease remains poorly understood. Exome sequencing of a familial MPN pedigree followed by a case-control analysis identified germline variants in the HER2/ERBB2 gene that associate with the MPN phenotype. ERBB2/HER2 is a novel susceptibility locus which contributes to cancer risk in combination with additional risk alleles. Familial cases of myeloproliferative neoplasms (MPN) are relatively common, yet few inherited risk factors have been identified. Exome sequencing of a kindred with a familial cancer syndrome characterized by both MPN and melanoma produced a germline variant in the ERBB2/HER2 gene that co-segregates with disease. To further investigate whether germline ERBB2 variants contribute to MPN predisposition, the frequency of ERBB2 variants was analyzed in 1604 cases that underwent evaluation for hematologic malignancy, including 236 cases of MPN. MPN cases had a higher frequency of rare germline ERBB2 coding variants compared to non-MPN hematologic malignancies (8.9% vs. 4.1%, OR 2.4, 95% CI: 1.4 to 4.0, p = 0.0028) as well as cases without a blood cancer diagnosis that served as an internal control (8.9% vs. 2.7%, OR 3.5, 95% CI: 1.4 to 8.3, p = 0.0053). This finding was validated via comparison to an independent control cohort of 1587 cases without selection for hematologic malignancy (8.9% in MPN cases vs. 5.2% in controls, p = 0.040). The most frequent variant identified, ERBB2 c.1960A > G; p.I654V, was present in MPN cases at more than twice its expected frequency. These data indicate that rare germline coding variants in ERBB2 are associated with an increased risk for development of MPN. The ERBB2 gene is a novel susceptibility locus which likely contributes to cancer risk in combination with additional risk alleles.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Future options in the treatment of ErbB2 (HER2)-positive breast cancer
    Fumoleau, Pierre
    EJC SUPPLEMENTS, 2008, 6 (05): : 25 - 31
  • [32] Tucatinib HER2 (ErbB2) inhibitor Treatment of breast and colorectal cancer
    Patil, T.
    Shagisultanova, E.
    Borges, V. F.
    DRUGS OF THE FUTURE, 2019, 44 (01) : 11 - 19
  • [33] When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) Oncogene
    Chow, Amy
    Arteaga, Carlos L.
    Wang, Shizhen Emily
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2011, 16 (02) : 81 - 88
  • [34] HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing
    Wong, Adele
    Bhan, Atul
    Lennerz, Jochen K.
    Brachtel, Elena
    LABORATORY INVESTIGATION, 2017, 97 : 522A - 522A
  • [35] Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors
    Grob, Tobias
    Sandmann, Mareike
    Quaas, Alexander
    Marx, Andreas
    Sauter, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] COMPLETE - Study the ErbB2 (HER2) - positive Breast cancer.
    Arnheim, Katharina
    Aktas, Bahriye
    ONKOLOGIE, 2010, 33 (04):
  • [37] ERBB2 (HER2) Gene Amplification and Protein Overexpression in Ampullary Carcinoma
    Hechtman, Jaclyn
    Arcila, Maria
    Vakiani, Efsevia
    Shia, Jinru
    Klimstra, David
    LABORATORY INVESTIGATION, 2015, 95 : 165A - 165A
  • [38] When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) Oncogene
    Amy Chow
    Carlos L. Arteaga
    Shizhen Emily Wang
    Journal of Mammary Gland Biology and Neoplasia, 2011, 16 : 81 - 88
  • [39] The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer
    Lippa, Blaise
    Kauffman, Goss S.
    Arcari, Joel
    Kwan, Tricia
    Chen, Jinshan
    Hungerford, William
    Bhattacharya, Samit
    Zhao, Xumiao
    Williams, Courtney
    Xiao, Jun
    Pustilnik, Leslie
    Su, Chunyan
    Moyer, James D.
    Ma, Ling
    Campbell, Mary
    Steyn, Stefanus
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (11) : 3081 - 3086
  • [40] erbB1/HER1和erbB2/HER2在肺癌的表达
    邓在春
    俞文英
    胡国平
    郑如恒
    张敦华
    谭云山
    徐永华
    江万里
    现代实用医学, 2001, (11) : 539 - 541